Product Images Secuado

This is a table showing the fold change and 90% confidence interval for PK Cmax and AUC in different population groups. The groups include individuals with mild, moderate, and severe renal impairment, mild, moderate, and severe hepatic impairment, smokers, and Japanese individuals. The values shown are relative to reference groups, such as normal renal and hepatic function, non-smokers, and Caucasians.*

This text provides information on the effect of various drugs on CYP enzymes and UGT1A4. It lists the inhibitors and inducers of these enzymes, along with their impact on PK (fold change and 90% CI). The text also mentions a specific interaction between fluvoxamine and asenapine where co-administration leads to an increase in asenapine exposure. It warns that a therapeutic dose of fluvoxamine may cause even greater increases in asenapine exposure. Overall, this text serves as a reference for drugs that can impact the metabolism and exposure of other drugs, which is crucial information for medical practitioners to consider when prescribing medications.*

This text provides information on the change in PK fold change and 90% CI for various CYP enzyme substrates and inhibitors including Paroxetine, Imipramine, and Desipramine. The effects of Asenapine on the inhibitory effects of Paroxetine on its own metabolism are also discussed. Asenapine is indicated to be a weak inhibitor of CYP2D6. Co-administration of Asenapine with various drugs did not affect their plasma concentrations.*

This text contains a graph showing the risk of relapse/impending relapse for subjects receiving Sublingual Asenapine compared to those receiving Placebo. The risk is plotted against time (in days) and the graph is based on Kaplan-Meier distribution with censoring at last double-blind dose date.*

This is a description of a medication called Secuado, which is a transdermal system delivering 5.7 mg/24 hours of asenapine. It comes in a box containing 30 transdermal systems, and each system contains 95 mg asenapine. The dosage and administration of the medication are described, and it is advised to keep the transdermal systems out of reach of children. The text also includes information about the manufacturer, Therapeutics LLC.*

This appears to be a description of a medication, specifically a transdermal system for the drug asenapine. The system contains 7.6mg of medication per 24-hour period and is administered via a patch that is applied immediately upon removal from its packaging. The instructions for use should be carefully read and followed, and the product should be kept out of reach of children and stored at room temperature. The text also includes details about the product's packaging and composition, as well as a warning that it is not to be used except as directed by a physician.*

Secuado is a 3.8 mg/24 hour transdermal system that contains acyclic saturated hydrocarbon sesi, Seryl pyruvate, isopropyl palmitate, malic acid, and sodium malate as active ingredients. It also includes polyester film backing, polyisobutylene, and other excipients. The manufacturer and distributor of Secuado are Hisamitsu Pharmaceutical Co., Inc. and Noven Therapeutics, LLC, respectively. Further details are not available due to poor quality.*

This is a description of a transdermal system containing 5.7 mg/24 hours of asenapine, which is to be used only for transdermal application. The system comprises 3.6 g asenapine, along with inactive ingredients such as hydrocarbons, silicone-treated polyester, and styrene-sopree-syene lock aplymer. The dosage and administration instructions are mentioned in the package insert. Users should follow the instructions for proper application and avoid wearing more than one Secuadoran transdermal system at a time. The used transdermal system should be folded and disposed of carefully, away from children. The product should be stored at room temperature (20°C to 25°C). The transdermal system is manufactured by Hisamitsu Pharmaceutical Co. and distributed by Noven Therapeutics, LLC.*

Secuado is a transdermal system medication containing asenapine used for transdermal use only. Each pack contains 40 systems with 7.6mg/24 hours of asenapine. The medication should be applied immediately after removing it from the pouch and must not be worn more than once. Proper usage and dosage instructions are mentioned in the package. The medication must be kept out of reach of children and not stored in the refrigerator. It should be kept at room temperature between 20-25°C (68-77°F). The manufacturer of the medication is Hisamitsu Pharmaceutical Co, Inc. and it is distributed by Noven Therapeutics, LLC.*